Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
作者信息
Moris Lisa, Mottet Nicolas, Wiegel Thomas
机构信息
Department of Urology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium.
Department of Urology, University Hospital, St. Etienne, France.
出版信息
Eur Urol. 2020 Sep;78(3):e116-e117. doi: 10.1016/j.eururo.2020.05.036. Epub 2020 Jun 11.
PMID:32536484
Abstract
摘要
相似文献
1
Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
Eur Urol. 2020 Sep;78(3):e116-e117. doi: 10.1016/j.eururo.2020.05.036. Epub 2020 Jun 11.
2
Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
Eur Urol. 2020 Sep;78(3):e120-e121. doi: 10.1016/j.eururo.2020.07.005. Epub 2020 Jul 16.
3
Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
Eur Urol. 2020 Sep;78(3):e118-e119. doi: 10.1016/j.eururo.2020.06.057. Epub 2020 Jul 15.
4
Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
Eur Urol. 2020 Sep;78(3):e114-e115. doi: 10.1016/j.eururo.2020.05.034. Epub 2020 Jun 10.
5
Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
Eur Urol. 2020 Nov;78(5):e192. doi: 10.1016/j.eururo.2020.07.031. Epub 2020 Aug 13.
6
Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
Eur Urol. 2020 Nov;78(5):e193-e194. doi: 10.1016/j.eururo.2020.07.041. Epub 2020 Aug 21.
7
Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
Eur Urol. 2019 May;75(5):e131-e132. doi: 10.1016/j.eururo.2018.12.024. Epub 2019 Jan 4.
8
Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.回复周雪亮和韩新伟致编辑的信，内容涉及：托马斯·范登布罗克、罗德里克·C·N·范登伯格、尼古拉斯·阿尔菲等人。前列腺癌根治性治疗后生化复发的预后价值：一项系统评价。《欧洲泌尿外科杂志》2019年；75卷：967 - 87页。
Eur Urol. 2019 Jul;76(1):e16. doi: 10.1016/j.eururo.2019.03.027. Epub 2019 Apr 6.
9
Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.回复：托马斯·范登布罗克、罗德里克·C·N·范登伯格、尼古拉斯·阿尔菲等。前列腺癌根治性治疗后生化复发的预后价值：一项系统评价。《欧洲泌尿外科杂志》2019年；75卷：967 - 87页。
Eur Urol. 2019 Jul;76(1):e15. doi: 10.1016/j.eururo.2019.03.028. Epub 2019 Apr 1.
10
Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.对托马斯·范登·布罗克、R.杰弗里·卡恩斯和史蒂文·乔尼奥的致编辑信的回复，信的内容涉及阿马尔·U.基尚、塔尔哈·谢赫、平杰·王等人的《接受放疗或根治性前列腺切除术的 Gleason 评分 9 - 10 前列腺腺癌患者的临床结局：多机构比较分析》。《欧洲泌尿外科杂志》2017 年；71:766 - 73。
Eur Urol. 2017 Nov;72(5):e123-e124. doi: 10.1016/j.eururo.2017.01.017. Epub 2017 Jan 19.
Zotero 插件